Immune Drivers in Autoimmune Cytopenias Inform Patient Care

Autoimmune cytopenias are characterized by the immune system's destruction of circulating blood cells, leading to conditions such as ITP, AIHA, and AIN. Despite their shared autoimmune etiology, the underlying immune dysregulation can vary significantly among patients, influencing disease severity, chronicity, and response to therapy. Current treatment approaches often rely on corticosteroids, intravenous immunoglobulin (IVIg), or splenectomy, which provide broad immunosuppression but lack specificity and can be associated with considerable side effects and incomplete responses.¹ These conditions represent a significant clinical challenge, often requiring long-term management and impacting patients' quality of life. The prevalence of ITP, for instance, is estimated to be between 1 in 10,000 and 1 in 20,000 adults, with varying incidence rates across different age groups and geographical regions. AIHA is less common but still affects a substantial number of individuals, with an estimated incidence of 1-3 per 100,000 per year. AIN is rarer, often presenting in pediatric populations or as a secondary condition. Understanding the diverse patient populations affected by these conditions is crucial for developing more effective and personalized treatment strategies.

The heterogeneity of these conditions underscores the importance of identifying specific immune drivers to facilitate targeted therapeutic interventions. For instance, ITP is primarily mediated by autoantibodies against platelet glycoproteins, leading to accelerated platelet destruction and impaired platelet production. However, the cellular immune response, particularly T-cell dysregulation, also plays a significant role.² Similarly, AIHA involves autoantibodies targeting red blood cell antigens, often complemented by T-cell mediated mechanisms.³ AIN, while less common, also involves autoantibody-mediated neutrophil destruction, with varying contributions from cellular immunity.⁴

Understanding Immune Drivers and Therapeutic Implications

Recent advancements in immunophenotyping techniques have enabled a more granular understanding of the specific immune cell populations and molecular pathways contributing to autoimmune cytopenias. Discussions at EHA 2026 emphasized the identification of distinct B-cell and T-cell subsets that correlate with disease activity and treatment response. For example, in ITP, an imbalance between T-helper 17 (Th17) cells and regulatory T (Treg) cells has been observed, with an increased Th17/Treg ratio often associated with disease severity.⁵ Furthermore, aberrant B-cell activation and the presence of pathogenic autoantibody-producing plasma cells are central to the pathogenesis of ITP and AIHA.⁶ These immunophenotyping methods often involve flow cytometry or mass cytometry, allowing for multi-parameter analysis of cell surface markers and intracellular proteins from peripheral blood samples. This detailed cellular profiling provides insights into the functional state and differentiation pathways of immune cells, moving beyond simple cell counts to reveal the specific immune abnormalities driving disease.

The characterization of these immune drivers has direct implications for patient care. For patients with ITP refractory to first-line therapies, the presence of specific B-cell populations might indicate a better response to B-cell depleting agents such as rituximab.⁷ Rituximab, a chimeric monoclonal antibody, targets the CD20 protein on B cells, leading to their depletion and a reduction in autoantibody production. Conversely, patients with predominant T-cell dysregulation might benefit from therapies targeting specific T-cell pathways. For example, studies are exploring the efficacy of Bruton's tyrosine kinase (BTK) inhibitors, which can modulate both B-cell and myeloid cell signaling, in refractory ITP.⁸ BTK inhibitors interfere with intracellular signaling pathways critical for B-cell development and function, offering a more precise mechanism of action compared to broad immunosuppressants. While specific HR or p-values from large-scale trials were not presented as definitive, the mechanistic understanding supports these targeted approaches. The focus remains on moving beyond broad immunosuppression to therapies that specifically address the identified immune abnormalities.⁹

In AIHA, the presence of warm autoantibodies (IgG) versus cold autoantibodies (IgM) dictates different therapeutic strategies. Warm AIHA often responds to corticosteroids and rituximab, while cold agglutinin disease (CAD), a form of cold AIHA, may require complement inhibitors.¹⁰ The EHA 2026 discussions highlighted ongoing research into novel complement pathway inhibitors and their potential to reduce hemolysis in CAD, offering a more targeted approach than traditional immunosuppressants.¹¹ These inhibitors block specific components of the complement cascade, preventing the destruction of red blood cells mediated by cold autoantibodies. This approach minimizes systemic immunosuppression, potentially reducing the risk of infections and other side effects associated with broader treatments.

The clinical utility of advanced immunophenotyping extends to predicting treatment response and identifying patients at risk of relapse. For instance, monitoring changes in specific T-cell subsets or B-cell populations during therapy could provide early indicators of treatment efficacy or failure, allowing for timely adjustments to the treatment regimen.¹² While the widespread availability and standardization of these advanced immunophenotyping techniques are still evolving, their integration into clinical practice holds the promise of more personalized and effective management strategies for patients with autoimmune cytopenias.¹³ However, limitations include the cost and technical expertise required for these assays, as well as the need for larger prospective studies to validate specific immune biomarkers across diverse patient cohorts and establish clear clinical decision-making algorithms. Further research is necessary to overcome these hurdles and translate these scientific advancements into routine clinical care.